COVID‐19 vaccine (mRNA BNT162b2) and COVID‐19 infection‐induced thrombotic thrombocytopenic purpura in adolescents

The mRNA COVID‐19 vaccine and COVID‐19 infection caused by the SARS‐CoV‐2 virus may be immunologic triggers for the development of thrombotic thrombocytopenic purpura (TTP). There is not yet literature that discusses TTP induced by COVID‐19 vaccination or infection in pediatric or adolescent patient...

Full description

Saved in:
Bibliographic Details
Published inPediatric blood & cancer Vol. 69; no. 6; pp. e29681 - n/a
Main Authors Vorster, Luna, Kirk, Susan E., Muscal, Eyal, Despotovic, Jenny M., Cohen, Clay T., Sartain, Sarah E.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.06.2022
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The mRNA COVID‐19 vaccine and COVID‐19 infection caused by the SARS‐CoV‐2 virus may be immunologic triggers for the development of thrombotic thrombocytopenic purpura (TTP). There is not yet literature that discusses TTP induced by COVID‐19 vaccination or infection in pediatric or adolescent patients. We describe three adolescents presenting with TTP (both de novo and relapsed disease) following administration of the Pfizer COVID‐19 vaccine or after COVID‐19 infection. Our observations demonstrate that the Pfizer‐BioNTech mRNA vaccine and COVID‐19 infection can act as triggers for the development/relapse of both congenital and acquired TTP.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.29681